---

Lipids in Biochemistry - A Complete Guide from Basics

---

1. What Are Lipids?

• Compartmentalized (e.g., membrane-associated lipids, TAG droplets in adipocytes), or
• Transported in blood in association with proteins (lipoproteins or albumin)

• Major source of energy (more calorie-dense than carbohydrates or proteins)
• Provide the hydrophobic barrier that partitions aqueous contents of cells
• Fat-soluble vitamins (A, D, E, K) serve regulatory/coenzyme functions
• Prostaglandins and steroid hormones control homeostasis
• Structural components of cell membranes

---

2. Classification of Lipids

---

3. Fatty Acids - The Building Blocks

3a. Chain Length Classification

3b. Degree of Saturation

• Saturated fatty acids (SFA): No double bonds. The alkyl chain is extended and flexible; carbons rotate freely. Pack tightly together (higher melting point - solid at room temperature). Example: palmitic acid (C16:0), stearic acid (C18:0).
• Monounsaturated FA (MUFA): One double bond. Example: oleic acid (C18:1), found in olive oil.
• Polyunsaturated FA (PUFA): More than one double bond. Double bonds in natural fats are usually 3 carbons apart. Example: linoleic acid (C18:2), arachidonic acid (C20:4).

3c. Cis vs. Trans Configuration

• Cis-unsaturated FA: Have a fixed 30° bend at each double bond because two hydrogens are missing from the same side of the carbon double bond. Cannot pack tightly → lower melting points → liquid oils at room temperature.
• Trans FA: Result from industrial catalytic hydrogenation. Hydrogen is missing from each side of the double bond, so the chain is more linear, resembling saturated FA. Trans fats are solid at room temperature and are associated with increased cardiovascular risk (ASCVD).

In mammals, all naturally occurring unsaturated fatty acids are the cis variety.

3d. Essential Fatty Acids

• Linoleic acid (omega-6) - from plants; converted to arachidonic acid
• Linolenic acid (omega-3) - from plants and marine sources

---

4. Triacylglycerols (TAG / Triglycerides)

• The major form of dietary fat (>90% of dietary lipid intake)
• The main energy storage form in adipose tissue
• More energy-dense than carbohydrates: oxidizing 1 mole of palmitic acid (C16) produces ~129 moles of ATP vs. ~38 moles of ATP from glucose

---

5. Phospholipids

Glycerophospholipids

• Glycerol backbone with 2 FA chains at positions sn-1 and sn-2
• Phosphate group at sn-3 linked to a polar head group
• Common types:
  • Phosphatidylcholine (lecithin) - most abundant membrane phospholipid
  • Phosphatidylethanolamine (PE) - inner membrane leaflet
  • Phosphatidylserine - inner leaflet, involved in apoptosis signaling
  • Phosphatidylinositol - precursor to second messengers (IP3, DAG)

Sphingomyelin

• Sphingosine backbone (not glycerol)
• One FA attached via amide bond (ceramide)
• Phosphocholine head group
• Major component of myelin sheath

---

6. Cholesterol - Structure and Roles

• Four fused hydrocarbon rings (A-D) = the steroid nucleus
• 8-carbon branched hydrocarbon chain at C-17
• Hydroxyl group at C-3 of ring A
• Double bond between C-5 and C-6 of ring B

• Structural component of cell membranes (modulates fluidity)
• Precursor for bile acids
• Precursor for steroid hormones (cortisol, aldosterone, testosterone, estrogen, progesterone)
• Precursor for vitamin D
• ~70% of plasma cholesterol is in LDL

---

7. Lipid Digestion and Absorption

• Fatty acids and monoglycerides enter intestinal epithelial cells
• Re-esterified back into TAG in the smooth ER
• Packaged into chylomicrons with apolipoprotein B-48
• Released into lymphatics (not portal blood) via the thoracic duct into the bloodstream

---

8. Lipoproteins - Transport in Blood

Types of Lipoproteins

Metabolism Pathways

1. Dietary fat absorbed → chylomicrons assembled in intestinal cells with Apo B-48
2. Enter lymphatics → bloodstream
3. In capillaries: Apo C-II activates lipoprotein lipase (LPL), which hydrolyzes TAG
4. FA taken up by muscle (energy) and adipose (storage)
5. Chylomicron remnants taken up by liver (via Apo E receptor)

1. Liver synthesizes VLDL containing Apo B-100 + TAG
2. VLDL → IDL (after LPL removes TAG) → LDL (after further TAG removal by hepatic lipase)
3. LDL delivers cholesterol to peripheral tissues via LDL receptor (Apo B-100/E receptor)
4. Receptor-mediated endocytosis: LDL binds → clathrin-coated pit → endosome → lysosome → cholesterol released

1. HDL is nascent (disk-shaped) from liver/intestine
2. Acquires cholesterol from peripheral tissues via LCAT (lecithin:cholesterol acyltransferase; activated by Apo A-I)
3. LCAT esterifies cholesterol → moves to HDL core
4. Mature spherical HDL returns to liver → cholesterol excreted in bile

---

9. Fatty Acid Synthesis (De Novo Lipogenesis)

Key Steps:

1. Acetyl-CoA exits mitochondria as citrate (CoA cannot cross the inner mitochondrial membrane; acetyl group is shuttled out via the citrate shuttle)
2. Acetyl-CoA carboxylation → Malonyl-CoA (rate-limiting step)
   • Enzyme: Acetyl-CoA carboxylase (ACC)
   • Cofactor: Biotin (Vitamin B7)
   • Requires ATP
   • Activated by: citrate, insulin
   • Inhibited by: palmitoyl-CoA, glucagon, epinephrine
3. Fatty acid synthase (FAS) complex - a multifunctional enzyme that repeats a 4-step cycle:
   • Condensation
   • Reduction (NADPH)
   • Dehydration
   • Reduction (NADPH again)
   • Each cycle adds 2 carbons from malonyl-CoA
   • Product of 7 cycles: Palmitate (C16:0)

Net equation: Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH + 14 H⁺ → Palmitate + 7 CO₂ + 8 CoA + 14 NADP⁺ + 6 H₂O

---

10. Fatty Acid Catabolism (Beta-Oxidation)

The Beta-Oxidation Cycle (4 steps per turn):

1. Oxidation (FAD → FADH₂)
2. Hydration
3. Oxidation (NAD⁺ → NADH)
4. Thiolysis - releases acetyl-CoA + shorter acyl-CoA (by 2 carbons)

• 7 turns of beta-oxidation → 8 acetyl-CoA + 7 FADH₂ + 7 NADH
• 8 acetyl-CoA enter the TCA (Krebs) cycle
• Total ATP yield: ~129 moles of ATP per mole of palmitate

---

11. Cholesterol Synthesis (Mevalonate Pathway)

Steps:

1. 2 Acetyl-CoA → Acetoacetyl-CoA (thiolase)
2. Acetoacetyl-CoA + Acetyl-CoA → HMG-CoA (HMG-CoA synthase)
3. HMG-CoA → Mevalonate ← RATE-LIMITING STEP
   • Enzyme: HMG-CoA reductase (target of statins)
   • Requires 2 NADPH
   • Inhibited by: high intracellular cholesterol (feedback), statins, bile acids
4. Mevalonate → Isopentenyl pyrophosphate (IPP) (5-carbon isoprene unit)
5. IPP → Geranyl-PP → Farnesyl-PP → Squalene → Lanosterol → Cholesterol
   • Farnesyl-PP is also used for protein prenylation (e.g., Ras protein anchoring)

• Transcriptional: SREBP-2 (sterol regulatory element binding protein) - when cholesterol is low, SREBP-2 is activated → increases HMG-CoA reductase expression
• Post-translational: phosphorylation inactivates; dephosphorylation activates
• Degradation: accelerated by high intracellular cholesterol

---

12. Bile Acid Synthesis

• Primary bile acids: Cholic acid (triol) and Chenodeoxycholic acid (diol)
• Rate-limiting enzyme: Cholesterol 7-alpha-hydroxylase (in SER)
• Bile acids are conjugated with glycine or taurine before secretion
• In the intestine, bacteria convert them to secondary bile acids (deoxycholic acid, lithocholic acid)
• ~95% are reabsorbed in the terminal ileum → enterohepatic circulation

---

13. Clinical Correlations

---

14. Summary Diagram - The Big Picture

Diet (TAG, Cholesterol)
        ↓
   [Gut - Digestion + Emulsification by bile acids]
        ↓
  Chylomicrons (Apo B-48)
        ↓ [LPL in capillaries]
  Fatty acids → Muscle (energy) / Adipose (storage)
  Remnants → Liver

Liver synthesizes:
  Acetyl-CoA → Fatty acids (FAS) → TAG
  Acetyl-CoA → Cholesterol (HMG-CoA reductase ← target of STATINS)
        ↓
  VLDL (Apo B-100) → IDL → LDL
                              ↓
                   Peripheral cells (via LDL receptor)
                              ↓
                   Cholesterol homeostasis (ACAT, SREBP-2)

Peripheral cholesterol → HDL (Apo A-I) → Liver [Reverse cholesterol transport]

---

---

Lipid Metabolism - Complete Biochemistry Guide

1. Lipolysis (fat mobilization from adipose)
2. Fatty acid oxidation (beta-oxidation)
3. Fatty acid synthesis (de novo lipogenesis)
4. Ketogenesis and ketolysis
5. Lipoprotein metabolism (transport pathways)
6. Cholesterol metabolism

---

1. Overview of Lipid Storage and Mobilization

Lipolysis (TAG Breakdown in Adipose)

• Epinephrine/glucagon (fasting): bind beta-adrenergic receptors → adenylyl cyclase → cAMP → PKA → phosphorylates and activates perilipins and HSL → lipolysis ON
• Insulin (fed state): dephosphorylates and inactivates HSL, suppresses ATGL expression → lipolysis OFF

• Glycerol - cannot be used by adipocytes (no glycerol kinase). Travels to liver → converted to DHAP → enters glycolysis or gluconeogenesis
• Free fatty acids (FFA) - bind albumin in blood, transported to muscles (energy) and liver. Cannot be used by RBCs (no mitochondria) or brain (to any significant extent)

---

2. Fatty Acid Activation and the Carnitine Shuttle

1. CPT-I (carnitine palmitoyltransferase I) - outer mitochondrial membrane; transfers acyl group from CoA to carnitine → acylcarnitine. This is the rate-limiting step
2. Translocase - transports acylcarnitine in, free carnitine out
3. CPT-II - inner mitochondrial membrane; transfers acyl group back to CoA in the matrix

Key inhibitor: Malonyl-CoA inhibits CPT-I, thus when fatty acid synthesis is active (malonyl-CoA is elevated), fatty acid oxidation is simultaneously blocked. This prevents a futile cycle.

---

3. Beta-Oxidation (Fatty Acid Catabolism)

The 4-step Repeating Cycle

Energy Yield - Palmitate (C16:0)

• 7 cycles of beta-oxidation produce:
  • 8 acetyl-CoA
  • 7 FADH₂ → 7 × 1.5 ATP = 10.5 ATP
  • 7 NADH → 7 × 2.5 ATP = 17.5 ATP
• 8 acetyl-CoA enter TCA cycle → 8 × 10 ATP = 80 ATP
• Minus 2 ATP for activation
• Net: ~106 ATP per palmitate molecule

Special Oxidation Pathways

---

4. Ketogenesis and Ketolysis

Why Ketone Bodies Are Made

• Inhibits pyruvate dehydrogenase (PDH)
• Activates pyruvate carboxylase (PC) → OAA
• But OAA is diverted to gluconeogenesis, not TCA
• Also: fatty acid oxidation raises NADH, which shifts OAA → malate
• Result: OAA unavailable for TCA → acetyl-CoA accumulates → ketogenesis

Ketogenesis (in liver only)

1. 2 Acetyl-CoA → Acetoacetyl-CoA (thiolase, reversal)
2. Acetoacetyl-CoA + Acetyl-CoA → HMG-CoA - rate-limiting; HMG-CoA synthase (mitochondrial; present in significant amounts only in liver)
3. HMG-CoA → Acetoacetate + Acetyl-CoA (HMG-CoA lyase)
4. Acetoacetate + NADH → 3-Hydroxybutyrate (3-hydroxybutyrate dehydrogenase); high NADH ratio during FA oxidation favors this direction
5. Acetoacetate → Acetone (spontaneous, non-enzymatic decarboxylation; produces fruity breath in DKA)

Ketolysis (in peripheral tissues - muscle, brain, kidney)

1. 3-Hydroxybutyrate → Acetoacetate + NADH (3-hydroxybutyrate dehydrogenase)
2. Acetoacetate + Succinyl-CoA → Acetoacetyl-CoA + Succinate (thiophorase / succinyl-CoA:acetoacetate CoA transferase - the enzyme absent in liver)
3. Acetoacetyl-CoA → 2 Acetyl-CoA (thiolase) → enter TCA cycle

In prolonged starvation (>2-3 weeks), plasma ketone bodies reach high levels and the brain switches from glucose to ketone bodies as its primary fuel - sparing glucose and thus preventing excessive muscle protein breakdown.

Diabetic Ketoacidosis (DKA)

---

5. Fatty Acid Synthesis (De Novo Lipogenesis)

Step 1 - Getting Acetyl-CoA to Cytosol (Citrate Shuttle)

Step 2 - Rate-Limiting Step: Acetyl-CoA → Malonyl-CoA

• Cofactor: Biotin (Vitamin B7)
• Reaction: Acetyl-CoA + CO₂ + ATP → Malonyl-CoA
• Allosteric activation: Citrate (signal of energy surplus)
• Allosteric inhibition: Palmitoyl-CoA (end-product feedback)
• Hormonal activation: Insulin (promotes dephosphorylation → active form)
• Hormonal inhibition: Glucagon, epinephrine (promote phosphorylation → inactive)

Step 3 - Fatty Acid Synthase (FAS) Complex

Net: Acetyl-CoA + 7 Malonyl-CoA + 14 NADPH → Palmitate + 7 CO₂ + 8 CoA + 14 NADP⁺ + 6 H₂O

• Pentose phosphate pathway (major source)
• Malic enzyme (malate → pyruvate + NADPH)

---

6. Lipoprotein Metabolism - Transport in Blood

Lipoprotein Classification

---

Pathway A: Exogenous Pathway (Dietary Fat Transport)

1. Intestinal cells absorb dietary FA + 2-monoglyceride → re-esterify to TAG → assembled into chylomicrons with Apo B-48 (unique to intestinal chylomicrons)
2. Chylomicrons leave via lymphatics (thoracic duct → left subclavian vein)
3. In plasma: receive Apo C-II and Apo E from circulating HDL
4. Lipoprotein lipase (LPL) on capillary walls - activated by Apo C-II - hydrolyzes TAG → FA + glycerol
   • FA → muscle (energy) or adipose (storage)
   • Glycerol → liver
5. As TAG is removed, chylomicron shrinks → chylomicron remnant (retains Apo B-48 + Apo E, loses Apo C)
6. Remnants taken up by liver via Apo E receptor → receptor-mediated endocytosis → lysosomal degradation

---

Pathway B: Endogenous Pathway (Liver-Derived Fat Transport)

1. Liver synthesizes nascent VLDL containing Apo B-100 + endogenous TAG
2. VLDL gains Apo C-II and Apo E from HDL in plasma
3. LPL (activated by Apo C-II) degrades VLDL-TAG in capillaries → FA released to tissues
4. VLDL shrinks → IDL (intermediate density lipoprotein); Apo C-II and Apo E returned to HDL
5. IDL further processed by hepatic lipase → LDL (retains Apo B-100 only)

• LDL binds LDL receptor (recognizes Apo B-100) on peripheral cells or liver
• Receptor-mediated endocytosis via clathrin-coated pits
• Vesicle → endosome (pH drops) → LDL separates from receptor
• Receptor recycled; LDL → lysosome → hydrolysis → free cholesterol, FA, amino acids released
• Cholesterol homeostasis effects on the cell:
  • Inhibits HMG-CoA reductase (reduces de novo synthesis)
  • Downregulates LDL receptor expression
  • Activates ACAT (stores excess cholesterol as cholesteryl esters)

Familial Hypercholesterolemia (FH): Defect in LDL receptor → LDL-C very high → premature atherosclerosis. Also caused by Apo B-100 mutations or gain-of-function PCSK9 mutations (PCSK9 targets LDL receptor for degradation).

---

Pathway C: Reverse Cholesterol Transport (RCT) - HDL Pathway

1. Liver/intestine secrete nascent HDL (disc-shaped; Apo A-I + phospholipids)
2. Peripheral cells export cholesterol to HDL via ABCA1 transporter
3. LCAT (lecithin:cholesterol acyltransferase), activated by Apo A-I, esterifies cholesterol → cholesteryl ester moves to HDL core → nascent disc → HDL3 → HDL2 (spherical, CE-rich)
4. Some cholesteryl esters transferred from HDL to VLDL/LDL by CETP (cholesteryl ester transfer protein) in exchange for TAG
5. HDL2 delivers cholesteryl esters to the liver via SR-B1 receptor (selective lipid uptake, particle not endocytosed)
6. Lipid-depleted HDL3 is regenerated and recirculates

Tangier disease: Deficiency of ABCA1 → virtual absence of HDL → cholesterol accumulates in macrophages → orange tonsils, splenomegaly, neuropathy

---

7. Regulation of Lipid Metabolism - Hormonal Control

Key Regulatory Molecules

---

8. Phospholipid and Sphingolipid Metabolism

Phospholipid Synthesis

• CDP-choline pathway (Kennedy pathway): Choline → phosphocholine → CDP-choline + DAG → phosphatidylcholine (PC). This is the major route in liver.
• Phospholipid remodeling: Phospholipase A2 removes FA at sn-2; reacylation with a new FA

Sphingomyelin Synthesis

• Ceramide (sphingosine + FA via amide bond) + CDP-choline → sphingomyelin + DAG

Arachidonic Acid Cascade (from membrane phospholipids)

• Phospholipase A2 → releases arachidonic acid from membrane PC
• COX (cyclooxygenase) → prostaglandins, thromboxanes
• Lipoxygenase → leukotrienes
• Target of NSAIDs (inhibit COX), steroids (inhibit phospholipase A2)

---

9. Clinical Correlations

---

10. Integrated Overview - Fed vs. Fasted State

FED STATE (insulin high)
- Glucose → Acetyl-CoA → FA synthesis (ACC active, FAS active)
- Malonyl-CoA high → CPT-I inhibited → beta-oxidation OFF
- LPL active in adipose → FA uptake for storage
- Liver: glycogen + TAG synthesis

FASTED STATE (glucagon/epinephrine high)
- ACC phosphorylated → inactive → malonyl-CoA low
- CPT-I uninhibited → beta-oxidation ON
- HSL active → adipose lipolysis → FFA to blood → liver + muscle
- Liver: beta-oxidation + ketogenesis
- Muscle: primarily burns FA
- Brain: initially glucose, then ketone bodies (prolonged fasting)

---

---

Beta-Oxidation → Ketogenesis: The Sequential Link

Fatty acids (from adipose lipolysis)
        ↓
   [Carnitine Shuttle → Mitochondrial matrix]
        ↓
   BETA-OXIDATION
   (repeated cycles)
        ↓
   Acetyl-CoA  ←── this is the product
        ↓
   NORMALLY → enters TCA cycle (+ oxaloacetate → citrate)
        ↓
   BUT in fasting/starvation/T1DM:
   OAA is depleted (diverted to gluconeogenesis)
        ↓
   Acetyl-CoA has nowhere to go
        ↓
   KETOGENESIS
   (liver mitochondria only)

---

Why OAA Gets Depleted - The Key Trigger

1. NADH accumulates from beta-oxidation → the high NADH/NAD⁺ ratio shifts OAA to malate (malate dehydrogenase runs in reverse) → OAA effectively disappears from the mitochondrial pool
2. Glucagon signals the liver (in fasting) to use OAA for gluconeogenesis (via phosphoenolpyruvate carboxykinase/PEPCK) → OAA is consumed for glucose production instead of TCA

---

The Sequential Flow in Detail

---

Important Nuances

• Beta-oxidation runs → acetyl-CoA → directly enters TCA cycle → ATP production (muscle has abundant OAA)

• Beta-oxidation runs → acetyl-CoA → OAA gone → ketogenesis

---

Simple Summary

Beta-oxidation produces acetyl-CoA. Ketogenesis consumes that acetyl-CoA when the TCA cycle cannot. They are sequential, not competing pathways - ketogenesis is the overflow valve for beta-oxidation in the fasting liver.

---

Alcohol (Ethanol) Metabolism - Complete Biochemistry Guide

---

1. Absorption and Distribution

• 0-5% metabolized in gastric mucosal cells (tongue, esophagus, stomach)
• 85-98% metabolized in the liver (the primary site)
• 2-10% excreted unchanged via lungs and kidneys (the basis of breathalyzer testing)

---

2. The Two Major Pathways of Ethanol Oxidation

---

Pathway 1: Alcohol Dehydrogenase (ADH) - Major Route (~80-90%)

Ethanol + NAD⁺ → Acetaldehyde + NADH + H⁺ Enzyme: Alcohol dehydrogenase (ADH)

Acetaldehyde + NAD⁺ → Acetate + NADH + H⁺ Enzyme: Acetaldehyde dehydrogenase (ALDH) - low Km mitochondrial isoform (ALDH2)

• ADH is a cytosolic dimer; exists as a family of isoenzymes (ADH1 family has low Km for ethanol)
• ALDH2 has very low Km for acetaldehyde → rapidly clears the toxic acetaldehyde
• ~90% of generated acetaldehyde is metabolized to acetate in the liver

---

Pathway 2: Microsomal Ethanol-Oxidizing System (MEOS) - Minor Route (~10-20%)

Ethanol + NADPH + H⁺ + O₂ → Acetaldehyde + NADP⁺ + 2H₂O Principal enzyme: CYP2E1 (cytochrome P450 2E1) in the endoplasmic reticulum

• High Km for ethanol (~11 mM vs. 0.013-4 mM for ADH) → only becomes significant at high ethanol concentrations
• Inducible by chronic ethanol consumption (5-10 fold increase in CYP2E1 levels)
• Therefore chronic heavy drinkers metabolize proportionately more ethanol through MEOS
• Consumes NADPH (an energy cost) rather than producing NADH
• Generates reactive oxygen species (free radicals) - a major source of liver damage

---

The Overall Pathway and What Happens to Acetate

• Has no toxic effects
• Most enters the blood and is taken up by skeletal muscle and other extrahepatic tissues
• Activated to acetyl-CoA by acetyl-CoA synthetase (ACS): Acetate + CoA + ATP → Acetyl-CoA + AMP + PPi
• Acetyl-CoA enters the TCA cycle for energy production
• Only a small amount is metabolized further in the liver itself

---

3. The Central Problem: NADH Accumulation and the High NADH/NAD⁺ Ratio

• 1 NADH from ADH (cytosol)
• 1 NADH from ALDH (mitochondria)

---

4. Metabolic Consequences of the High NADH/NAD⁺ Ratio

(1) Inhibition of Beta-Oxidation → Fatty Liver

• High NADH inhibits beta-oxidation (the dehydrogenation steps of beta-oxidation require NAD⁺ and FAD, both of which are reduced)
• Fatty acids accumulate in the liver
• Combined with increased glycerol-3-phosphate availability (DHAP → glycerol-3-P favored by high NADH), TAG synthesis increases
• TAG accumulates → hepatic steatosis (fatty liver) - the earliest and most common liver change in alcohol use
• Excess TAG also secreted as VLDL → hypertriglyceridemia

(2) Inhibition of TCA Cycle → Ketogenesis

• High NADH shifts OAA → malate (malate dehydrogenase runs in reverse)
• OAA unavailable to accept acetyl-CoA → TCA cycle blocked
• Acetyl-CoA accumulates → ketogenesis → alcoholic ketoacidosis
• Seen especially in people who drink heavily and eat poorly (combined starvation + alcohol)

(3) Inhibition of Gluconeogenesis → Hypoglycemia

• Gluconeogenesis from lactate requires NAD⁺ (lactate → pyruvate by LDH) - but NAD⁺ is depleted
• High NADH also diverts OAA away from gluconeogenesis (OAA → malate)
• Both alanine and other gluconeogenic amino acids cannot be used efficiently
• Result: Hypoglycemia - particularly dangerous in fasting individuals who drink (e.g., a diabetic patient who skips meals and drinks alcohol)

(4) Lactic Acidosis

• High NADH pushes pyruvate → lactate (by lactate dehydrogenase)
• Lactate accumulates → lactic acidemia / lactic acidosis
• Combined with ketoacidosis, a severe anion-gap metabolic acidosis can result

(5) Hyperuricemia and Gout

• Lactate competes with uric acid for renal tubular secretion
• Uric acid excretion decreases → hyperuricemia → gout precipitation
• Explains why alcohol is a common trigger for gout attacks

(6) Impaired Drug Metabolism

• CYP2E1 induction by chronic alcohol increases metabolism of many drugs (tolerance - need more drug for same effect)
• But when alcohol is present acutely, it competes with and inhibits CYP2E1-mediated drug metabolism
• Example: acetaminophen (paracetamol) - normally a safe drug, but in chronic alcohol users, induced CYP2E1 generates much more of the toxic NAPQI metabolite → risk of hepatotoxicity at normal doses

---

5. Toxic Products of Ethanol Metabolism

Acetaldehyde Toxicity

• Protein adduct formation - covalently binds to amino groups on proteins, altering their function
• DNA adducts - mutagenic; contributes to hepatocarcinogenesis
• Mitochondrial damage - disrupts electron transport chain; leads to impaired beta-oxidation and oxidative phosphorylation
• Interferes with retinoic acid synthesis (ALDH competes with retinaldehyde oxidation) → contributes to fetal alcohol syndrome

Free Radical Formation (Oxidative Stress)

• CYP2E1 (MEOS) generates the hydroxyethyl radical (CH₃CH•OH) and other ROS
• Increased with CYP2E1 induction (chronic drinkers)
• Peroxidizes membrane phospholipids → mitochondrial membrane damage, cell necrosis
• Induces other P450s → activates hepatocarcinogens

---

6. Energy Yield of Ethanol

• Induction of MEOS shifts metabolism to the less efficient pathway
• Alcohol calories are "nutritionally empty" - no vitamins, essential amino acids, or micronutrients
• Chronic intake damages the liver, impairing metabolic utilization of all nutrients

---

7. Pharmacogenomics - Individual Variations

This is the basis for disulfiram (Antabuse) therapy: it inhibits ALDH → acetaldehyde accumulates → aversive flushing reaction → deters drinking

---

8. Spectrum of Alcohol-Induced Liver Disease

Acute ethanol → HIGH NADH/NAD⁺ ratio
        ↓
[Reversible]
Fatty Liver (Hepatic Steatosis)
- Accumulation of TAG in hepatocytes
- Asymptomatic; enlarged liver
- Fully reversible with abstinence

         ↓ (continued drinking + acetaldehyde + ROS)

[Potentially reversible]
Alcoholic Hepatitis
- Inflammation and hepatocyte necrosis
- Elevated AST, ALT (AST:ALT ratio >2 is characteristic of alcohol)
- Fever, jaundice, tender hepatomegaly

         ↓ (irreversible)

Cirrhosis
- Fibrosis and scarring
- Loss of liver architecture and blood flow
- Consequences: portal hypertension, ascites, varices,
  hepatic encephalopathy (↑ ammonia), coagulopathy,
  jaundice (↑ bilirubin), hypoalbuminemia → edema

---

9. Summary - The Big Picture

ETHANOL (CH₃CH₂OH)
        ↓
   [Liver - 2 routes]
        ↓
ADH (80-90%)         MEOS/CYP2E1 (10-20%)
NAD⁺ → NADH         NADPH + O₂ consumed
                     ROS generated (liver damage)
        ↓
ACETALDEHYDE  ←── TOXIC: adducts, DNA damage, mitochondrial injury
        ↓
ALDH (mitochondria)
NAD⁺ → NADH
        ↓
ACETATE → blood → muscle → Acetyl-CoA → TCA → CO₂ + ATP

CONSEQUENCE OF NADH EXCESS:
→ Beta-oxidation OFF → Fatty liver
→ TCA cycle OFF → Ketogenesis → Ketoacidosis
→ Gluconeogenesis OFF → Hypoglycemia
→ Pyruvate → Lactate → Lactic acidosis
→ Urate excretion blocked → Gout
→ Drug interactions via CYP2E1

---

---

MEOS (Microsomal Ethanol-Oxidizing System) - In Depth

---

1. What is MEOS?

---

2. The MEOS Reaction

Ethanol + NADPH + H⁺ + O₂ → Acetaldehyde + NADP⁺ + 2H₂O

---

3. Structure of the CYP2E1 Enzyme System

• Contains FAD + FMN (or Fe-S centers)
• Accepts electrons from NADPH and passes them as single electrons (e⁻) to the P450
• Acts as the electron-donating reductase system

• Contains an Fe-heme in the active site
• Has binding sites for both O₂ and the substrate (ethanol)
• Accepts electrons from the reductase, activates O₂
• Transfers one oxygen atom to the substrate (ethanol → acetaldehyde), the other oxygen is reduced to H₂O

• CYP = Cytochrome P450
• 2 = gene family (>40% amino acid sequence identity)
• E = subfamily (>55% sequence identity)
• 1 = individual isoenzyme number

---

4. Why the High Km of CYP2E1 Matters

---

5. Induction of MEOS by Chronic Ethanol

• Increases hepatic CYP2E1 levels by 5-10 fold
• Also causes 2-4 fold induction of other P450s (CYP2B, CYP3A, etc.)
• The entire smooth ER proliferates - more ER, more microsomal enzymes generally

• Transcriptional: increased CYP2E1 mRNA (gene induction + mRNA stabilization)
• Post-translational: the protein is stabilized against degradation (increased protein half-life) - this is the predominant mechanism
• Ethanol acts as its own inducer by binding to intracellular receptor proteins

1. Faster ethanol clearance → metabolic tolerance (chronic drinkers need more alcohol to feel the same effect)
2. More acetaldehyde produced faster than ALDH can handle → acetaldehyde overflow into blood → damage to other tissues
3. Greatly increased free radical generation → oxidative stress → hepatocyte injury
4. Cross-induction of other P450s → altered metabolism of many drugs

---

6. Free Radical Generation - The Core of MEOS Toxicity

Radicals produced:

What these radicals damage:

• Membrane phospholipids - lipid peroxidation, especially in the inner mitochondrial membrane → disrupts electron transport → uncouples ATP synthesis → more oxidative stress (a vicious cycle)
• Proteins - oxidation and adduct formation → loss of enzyme function
• DNA - mutations → hepatocarcinogenesis (CYP2E1 induction by alcohol is linked to increased liver cancer risk)
• Mitochondria - membrane damage leads to impaired beta-oxidation and oxidative phosphorylation

---

7. Drug Interactions via Induced MEOS - Critical Clinical Point

Scenario A: Chronic Alcohol + Drug (no alcohol currently)

Scenario B: Acute Alcohol + Drug (drinking now)

---

8. The Acetaminophen-Alcohol Interaction in Detail

ACETAMINOPHEN NORMALLY (>90%):
   Acetaminophen → (glucuronidation/sulfation) → harmless conjugates → excreted

ACETAMINOPHEN SMALL FRACTION (5-10%):
   Acetaminophen → (CYP2E1) → NAPQI (toxic!)
                                    ↓
              + Glutathione → mercapturic acid → excreted safely (detoxified)

IN CHRONIC ALCOHOL USER (CYP2E1 induced 5-10 fold):
   Much more acetaminophen → CYP2E1 pathway → MUCH MORE NAPQI
   + Alcohol also depletes glutathione stores
   = Glutathione overwhelmed
   = NAPQI binds hepatocyte proteins covalently → HEPATOCYTE NECROSIS

Key nuance: Acute ethanol + acetaminophen may actually be protective because ethanol competitively inhibits CYP2E1 (competing for the same active site), reducing NAPQI formation. But chronic ethanol use is dangerous because induced CYP2E1 generates far more NAPQI from even normal acetaminophen doses.

---

9. MEOS and the Fetal Alcohol Spectrum

• Direct ethanol and acetaldehyde
• Reactive oxygen species from fetal CYP2E1 activity
• Interference with retinoic acid synthesis (CYP competes with retinaldehyde oxidation by ALDH)

---

10. MEOS Summary - ADH vs. MEOS at a Glance

                    ADH PATHWAY              MEOS (CYP2E1)
Location:           Cytosol                  Smooth ER
Coenzyme:           NAD⁺ → NADH              NADPH + O₂
Km (ethanol):       Very low (high affinity)  High (low affinity)
Dominates when:     Normal drinking           Heavy/chronic drinking
Inducible?:         No                        Yes (5-10x by chronic ethanol)
Free radicals?:     Minimal                   Yes - major source
Energy effect:      Generates NADH (energy)   Consumes NADPH (energy cost)
Clinical concern:   Fatty liver, hypoglycemia  Oxidative damage, drug interactions
                    via NADH excess            hepatocarcinogenesis, NAPQI toxicity

---

---

Intracellular (Cellular) Accumulations - Complete Pathology Guide

---

Overview

• Cytoplasm
• Organelles (typically lysosomes)
• Nucleus

---

The 4 Fundamental Mechanisms

Key point: If the overload can be stopped or reversed, accumulation is often reversible. In inherited storage diseases, accumulation is progressive and may lead to cell death and patient death.

---

TYPE 1: Lipid Accumulations

---

1A. Steatosis (Fatty Change) - Triglyceride Accumulation

• Small vacuoles around nucleus (microvesicular) - acute injury, e.g., tetracycline toxicity, Reye syndrome, acute fatty liver of pregnancy
• Large single vacuole displacing nucleus to periphery (macrovesicular) - chronic, e.g., alcohol, NAFLD

• Initially: reversible, asymptomatic, hepatomegaly
• If persists: → inflammatory cytokines → steatohepatitis → fibrosis → cirrhosis
• NAFLD is now the most common cause of cryptogenic cirrhosis worldwide

• Heart (hypoxia, diphtheria toxin)
• Kidney
• Skeletal muscle

---

1B. Cholesterol and Cholesterol Ester Accumulation

• Form long needle-shaped clefts in tissue sections
• Activate the NLRP3 inflammasome in macrophages → IL-1β release → local inflammation → plaque progression

---

1C. Phospholipid Accumulation

• Component of myelin figures found in necrotic cells
• Accumulate in lysosomal storage diseases (see below)

---

TYPE 2: Protein Accumulations

---

2A. Reabsorption Droplets (Hyaline Droplets in Renal Tubules)

• Cause: Heavy proteinuria (nephrotic syndrome) → excess protein filtered across glomerulus → increased pinocytosis in proximal tubule → protein-filled pink hyaline droplets in cytoplasm
• Consequence: Reversible - if proteinuria resolves, droplets disappear
• Significance: Marker of ongoing glomerular damage

---

2B. Russell Bodies (Plasma Cells)

• Cause: Plasma cells engaged in excessive immunoglobulin synthesis → distended ER packed with immunoglobulins → large, homogeneous eosinophilic inclusions called Russell bodies
• Seen in: Chronic inflammation, multiple myeloma, plasmacytomas
• Consequence: Functional - plasma cell still active; not directly harmful

---

2C. α1-Antitrypsin Deficiency - Defective Protein Transport

• Cause: Mutations in α1-antitrypsin (AAT) gene slow protein folding → partially folded intermediates aggregate in ER of hepatocytes → PAS-positive diastase-resistant globules in hepatocyte cytoplasm
• Dual pathology:
  1. Loss of function in the lung: AAT normally inhibits neutrophil elastase. Deficiency → unchecked elastase activity → destruction of alveolar walls → emphysema (panacinar type)
  2. ER stress from misfolded protein accumulation → unfolded protein response → hepatocyte apoptosis → hepatitis and cirrhosis
• Consequence: Panlobular emphysema (especially lower lobes), liver cirrhosis, hepatocellular carcinoma

---

2D. Cytoskeletal Protein Accumulations

---

2E. Misfolded/Aggregated Proteins (Proteinopathies)

• Abnormal proteins that cannot be cleared by the ubiquitin-proteasome system accumulate and form toxic aggregates
• Both intracellular and extracellular deposition possible
• Examples: Amyloidosis (extracellular), Prion diseases, Huntington disease (intranuclear huntingtin inclusions)
• Mechanism of injury: Direct physical disruption + ER stress + activation of apoptosis

---

2F. Hyaline Change

---

TYPE 3: Glycogen Accumulations

• Glycogen in normal cells dissolves in aqueous fixatives → appears as clear vacuoles in H&E; identified by PAS stain (rose-violet) or Best carmine stain; confirmed by diastase digestion (removes glycogen → stain disappears)

---

TYPE 4: Pigment Accumulations

---

4A. Exogenous Pigments

---

4B. Endogenous Pigments

Lipofuscin ("Wear-and-Tear Pigment")

• Nature: Polymers of oxidized lipids and phospholipids complexed with protein - product of lipid peroxidation of polyunsaturated membrane lipids
• Appearance: Yellow-brown, finely granular, perinuclear, intralysosomal
• Significance: Telltale marker of free radical injury and oxidative stress; NOT directly injurious to the cell
• Seen in: Aging hepatocytes and cardiac myocytes; severe malnutrition; cancer cachexia
• Diseases association: Brown atrophy of heart/liver (seen in cachexia)

Melanin

• Nature: Endogenous brown-black pigment; produced by melanocytes from tyrosine (via tyrosinase)
• Normal location: Skin, hair follicles, iris, substantia nigra, locus coeruleus
• Pathologic accumulations:
  • Melanoma - malignant melanocytes produce excess melanin
  • Addison disease - excess ACTH/MSH → increased skin melanin → hyperpigmentation
  • Freckles, melanocytic nevi
  • Loss: Vitiligo (autoimmune melanocyte destruction), Albinism (tyrosinase deficiency)

Hemosiderin

• Nature: Golden-yellow to brown granular/crystalline pigment; aggregated ferritin micelles (iron storage form)
• Normal: Small amounts in bone marrow macrophages, spleen, liver (recycling senescent RBCs)
• Pathologic - local excess:
  • Bruise/hemorrhage: Extravasated RBCs → phagocytosed by macrophages → hemoglobin → heme → biliverdin (green) → bilirubin (yellow-green) → hemosiderin (brown/golden). This explains the color changes of a healing bruise (red → green → yellow → resolved)
• Pathologic - systemic excess (hemosiderosis):

• Consequences of iron overload:
  • Liver: Cirrhosis
  • Pancreas: "Bronze diabetes" (diabetes mellitus)
  • Heart: Cardiomyopathy
  • Skin: Bronze discoloration
  • Joints: Arthropathy
  • Pituitary/gonads: Hypogonadism

Bilirubin

• Product of heme catabolism
• Normally conjugated in liver and excreted in bile
• Accumulates in jaundice (icterus) - causes yellow discoloration of skin, sclerae, mucous membranes
• Types: Pre-hepatic (hemolysis), hepatic (hepatocellular disease), post-hepatic (biliary obstruction)

---

TYPE 5: Pathologic Calcification (Bonus - Related Accumulation)

---

Summary Table - All Cellular Accumulations

---